Please provide your email address to receive an email when new articles are posted on . Efficacy of once-weekly intravenous dalbavancin was comparable to twice-daily intravenous vancomycin for the ...

Hospitalized children given high-dose intravenous infusions of the antibiotic vancomycin to treat drug-resistant bacterial infections face an increased risk for kidney damage -- an often reversible ...

Vancomycin (as HCl) 500mg/vial, 1g/vial; lyophilized pwd for IV infusion after reconstitution and dilution. Not for prophylaxis of endophthalmitis. Renal insufficiency. Monitor hearing, blood, renal ...

Patients with skin or skin structure infections may have two 2 new antibiotic options, both of which had similar efficacy and safety profiles as vancomycin in phase 3, randomized controlled trials ...

Back-to-back papers in the June 5th issue of New England Journal of Medicine reported positive phase 3 clinical trial results for two new intravenous antibiotics in the treatment of nasty bacterial ...

Treating hospitalized children with the widely used combination antibiotic therapy of intravenous vancomycin hydrochloride and piperacillin-tazobactam (TZP) significantly increases their risk for ...

The antibiotic dalbavancin is as effective as vancomycin, the current standard-of-care antibiotic used to treat serious bacterial skin and skin-structure infections, research shows. The study results ...

VANCOMYCIN is a penicillinase-resistant antibiotic that may be used in the treatment of staphylococcal infections. Because it is known to be excreted chiefly through the kidneys in normal persons 1 ...

Reviewed by Robert Jasmer, MD, Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner The ...

McKinnon and his team have found out the benefits of oral ZYVOX for the treatment of skin infections and pneumonia caused by bacterial infections. McKinnon and his team have found out the benefits of ...

Please provide your email address to receive an email when new articles are posted on . In patients with posttraumatic elbow stiffness following elbow release, local application of vancomycin powder ...

LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix ...